Laina D. Mercer
YOU?
Author Swipe
View article: One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand
One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand Open
To promote self-reliance in vaccine production, a chimeric Newcastle Disease Virus (NDV) based vaccine (NDV-HXP-S) was developed in Bangkok, Thailand, with the support of PATH. The interim results of phase 1 on initial safety and immune re…
View article: Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial Open
Bill & Melinda Gates Foundation.
View article: Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic <i>Plasmodium falciparum</i>-Exposed, Drug-Treated Kenyan Adults
Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic <i>Plasmodium falciparum</i>-Exposed, Drug-Treated Kenyan Adults Open
Background RTS,S/AS01 vaccine efficacy (VE) was previously shown as lower in African adults than in malaria-naive US adults, potentially due to concurrent Plasmodium falciparum infections. We investigated whether treatment of infection pri…
View article: Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial Open
For the Bengali translation of the abstract see Supplementary Materials section.
View article: First-in-human, phase 1, randomized, observer-blind, controlled trial to assess the safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults
First-in-human, phase 1, randomized, observer-blind, controlled trial to assess the safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults Open
Background Reducing the risks of vaccine-derived polioviruses and vaccine-associated paralytic poliomyelitis from type 1 or 3 Sabin-strain oral poliovirus vaccines (OPVs) motivated the development of novel type 1 and 3 OPVs (nOPV1, nOPV3),…
View article: A Multi-Center, Observer-Blind, Randomized, Phase 3 Study to Evaluate Safety, Non-Inferiority of Multi-Dose and Single-Dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) and Lot-to-Lot Consistency of the Immune Response to Multi-Dose Vial Formulation EuTCV in Healthy Participants in Kenya and Senegal
A Multi-Center, Observer-Blind, Randomized, Phase 3 Study to Evaluate Safety, Non-Inferiority of Multi-Dose and Single-Dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) and Lot-to-Lot Consistency of the Immune Response to Multi-Dose Vial Formulation EuTCV in Healthy Participants in Kenya and Senegal Open
View article: Immune Responses to a Heterologous Booster with Mrna Based Covid-19 Vaccine after Priming with an Inactivated Newcastle Disease Virus Recombinant Vaccine Expressing the Sars-Cov-2 Spike Protein (Ndv-Hxp-S)
Immune Responses to a Heterologous Booster with Mrna Based Covid-19 Vaccine after Priming with an Inactivated Newcastle Disease Virus Recombinant Vaccine Expressing the Sars-Cov-2 Spike Protein (Ndv-Hxp-S) Open
View article: Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial Open
Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and lower-middle-income countries is needed. NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the spike protein of se…
View article: Safety and Immunogenicity of a Nipah Virus Vaccine (Hev-Sg-V) in Adults: A Single-Centre, Randomised, Observer-Blind, Placebo-Controlled, Phase 1 Study
Safety and Immunogenicity of a Nipah Virus Vaccine (Hev-Sg-V) in Adults: A Single-Centre, Randomised, Observer-Blind, Placebo-Controlled, Phase 1 Study Open
View article: Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing Sars-Cov-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing Sars-Cov-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial Open
View article: Immunogenicity and Safety of Escherichia Coli-Produced Bivalent Human Papillomavirus Vaccine in Girls 9–14 Years of Age in Low- and Middle-Income Countries: Final Data of Randomized Controlled Trial
Immunogenicity and Safety of Escherichia Coli-Produced Bivalent Human Papillomavirus Vaccine in Girls 9–14 Years of Age in Low- and Middle-Income Countries: Final Data of Randomized Controlled Trial Open
View article: Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial Open
Summary Background Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and lower-middle-income countries is needed. NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the …
View article: Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy Open
Background The only licensed malaria vaccine, RTS,S/AS01 E , confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of sa…
View article: Socioeconomic, demographic and environmental factors inform malaria intervention prioritization in urban Nigeria
Socioeconomic, demographic and environmental factors inform malaria intervention prioritization in urban Nigeria Open
Background Nigeria is one of three countries projected to have the largest absolute increase in the size of its urban population and this could intensify malaria transmission in cities. Accelerated urban population growth is outpacing the …
View article: A subnational family planning estimation tool (SFPET) for estimating contraceptive use and unmet need by subnational areas and demographic subgroups
A subnational family planning estimation tool (SFPET) for estimating contraceptive use and unmet need by subnational areas and demographic subgroups Open
Background Access to safe, effective, and voluntary family planning (FP) is a fundamental human right and is an important step toward achieving gender equality and economic autonomy. Global organizations have set ambitious goals to create …
View article: Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials
Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials Open
Bill & Melinda Gates Foundation.
View article: Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing — Worldwide, March–October 2021
Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing — Worldwide, March–October 2021 Open
The emergence and international spread of neurovirulent circulating vaccine-derived polioviruses (cVDPVs) across multiple countries in Africa and Asia in recent years pose a major challenge to the goal of eradicating all forms of polioviru…
View article: Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam Open
View article: Socioeconomic, demographic and environmental factors inform intervention prioritization in urban Nigeria
Socioeconomic, demographic and environmental factors inform intervention prioritization in urban Nigeria Open
Nigeria is one of three countries projected to have the largest absolute increase in the size of its urban population and this could intensify malaria transmission in cities. Accelerated urban population growth is out-pacing the availabili…
View article: Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial Open
View article: Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children
Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children Open
View article: Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam
Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam Open
Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus (NDV) vaccine expressing the spike protein of severe acute r…
View article: Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial Open
Summary Background Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing the spike protein of s…
View article: Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses
Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses Open
View article: Estimating the levels and trends of family planning indicators in 436 sub-national areas across 26 countries in sub-Saharan Africa
Estimating the levels and trends of family planning indicators in 436 sub-national areas across 26 countries in sub-Saharan Africa Open
Background Scaling up access to safe, effective, and voluntary family planning (FP) services to achieve universal access for women and families will require increased commitment by countries and international organizations. On the way towa…
View article: Adult Female Overweight and Obesity Prevalence in Seven Sub-Saharan African Countries: A Baseline Sub-National Assessment of Indicator 14 Of the Global NCD Monitoring Framework
Adult Female Overweight and Obesity Prevalence in Seven Sub-Saharan African Countries: A Baseline Sub-National Assessment of Indicator 14 Of the Global NCD Monitoring Framework Open
Introduction: Decreasing overweight and obesity prevalence requires precise data at sub-national levels to monitor progress and initiate interventions. This study aimed to estimate baseline age-standardized overweight prevalence at the low…
View article: Evaluating the Impact of Programmatic Mass Drug Administration for Malaria in Zambia Using Routine Incidence Data
Evaluating the Impact of Programmatic Mass Drug Administration for Malaria in Zambia Using Routine Incidence Data Open
Background In 2016, the Zambian National Malaria Elimination Centre started programmatic mass drug administration (pMDA) campaigns with dihydroartemisinin-piperaquine as a malaria elimination tool in Southern Province. Two rounds were admi…
View article: Is the positive association between middle-income and rich household wealth and adult sub-Saharan African women’s overweight status modified by the level of education attainment? A cross-sectional study of 22 countries
Is the positive association between middle-income and rich household wealth and adult sub-Saharan African women’s overweight status modified by the level of education attainment? A cross-sectional study of 22 countries Open
View article: Impact of state weights on national vaccination coverage estimates from household surveys in Nigeria
Impact of state weights on national vaccination coverage estimates from household surveys in Nigeria Open
National vaccination coverage estimates from household surveys are widely used in monitoring and planning of immunization programs. In Nigeria, survey-reported national coverage estimates have shown large fluctuations in the past few years…
View article: Assessing differential impacts of COVID-19 on black communities
Assessing differential impacts of COVID-19 on black communities Open
Nearly 20% of U.S. counties are disproportionately black, and they accounted for 52% of COVID-19 diagnoses and 58% of COVID-19 deaths nationally. County-level comparisons can both inform COVID-19 responses and identify epidemic hot spots. …